Today’s Market Runner: Is PTC Therapeutics, Inc. a Buy? The Stock Rises Again

Today's Market Runner: Is PTC Therapeutics, Inc. a Buy? The Stock Rises Again

The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) is a huge mover today! The stock increased 4.94% or $0.58 on November 23, hitting $12.31. About 865,397 shares traded hands. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 48.31% since April 22, 2016 and is uptrending. It has outperformed by 42.90% the S&P500.
The move comes after 5 months positive chart setup for the $409.54M company. It was reported on Nov, 24 by We have $13.05 PT which if reached, will make NASDAQ:PTCT worth $24.57 million more.

Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on March, 6. They expect $-1.17 EPS, up 22.00% or $0.33 from last year’s $-1.5 per share. After $-1.03 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 13.59% negative EPS growth.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Out of 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. PTC Therapeutics has been the topic of 19 analyst reports since July 31, 2015 according to StockzIntelligence Inc. On Wednesday, November 25 the stock rating was downgraded by Jefferies to “Underperform”. The company was maintained on Thursday, February 25 by Oppenheimer. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Sector Perform” rating given on Friday, November 11 by RBC Capital Markets. The rating was downgraded by JP Morgan on Tuesday, February 23 to “Neutral”. The firm earned “Neutral” rating on Wednesday, February 24 by Citigroup. The rating was upgraded by Jefferies to “Hold” on Wednesday, February 24. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Outperform” rating by Oppenheimer on Friday, October 16. Credit Suisse downgraded the shares of PTCT in a report on Tuesday, July 26 to “Neutral” rating. The firm has “Buy” rating given on Tuesday, August 25 by Citigroup. RBC Capital Markets maintained the shares of PTCT in a report on Friday, October 16 with “Outperform” rating.

According to Zacks Investment Research, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.”

Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.23, from 1.23 in 2016Q1. The ratio dropped, as 17 funds sold all PTC Therapeutics, Inc. shares owned while 30 reduced positions. 17 funds bought stakes while 41 increased positions. They now own 28.13 million shares or 3.23% less from 29.06 million shares in 2016Q1.
Blackrock Inc, a New York-based fund reported 57,806 shares. Numeric Invsts Llc holds 126,400 shares or 0.01% of its portfolio. Oppenheimer Com last reported 87,456 shares in the company. Bogle Invest Management Limited Partnership De last reported 0.13% of its portfolio in the stock. Alliancebernstein Limited Partnership accumulated 0% or 75,650 shares. Geode Limited Company, a Massachusetts-based fund reported 225,753 shares. Moreover, Blackrock Gru has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 202,283 shares. Meeder Asset Management last reported 0.01% of its portfolio in the stock. Jennison Assoc Limited Co has 446,000 shares for 0% of their US portfolio. Middleton And Ma last reported 0.06% of its portfolio in the stock. Moreover, Panagora Asset has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 983 shares. Dimensional Fund Limited Partnership holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 100,783 shares. California Public Employees Retirement System has 0% invested in the company for 22,000 shares. Blackrock Advsrs holds 0.01% or 742,711 shares in its portfolio. Moreover, Mackenzie Financial has 0.01% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 138,200 shares.

More important recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: which released: “Why PTC Therapeutics, Advanced Micro Devices, and Nordstrom Jumped Today” on November 11, 2016, also published article titled: “Why PTC Therapeutics Is Soaring”, published: “Why PTC Therapeutics Is Rocketing 74% Today” on November 11, 2016. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) was released by: and their article: “PTC Therapeutics Reports Third Quarter 2016 Financial Results and Provides …” with publication date: November 02, 2016.

PTCT Company Profile

PTC Therapeutics, Inc., incorporated on March 31, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older in over 30 member states of the European Economic Area (EEA). It holds commercialization rights to Translarna for all indications in all territories, across the world. Translarna is designated as an orphan medicinal product for the treatment of cystic fibrosis (CF), duchenne muscular dystrophy (DMD), Mucopolysaccharidosis type I (MPS I), and aniridia. The Company’s programs include Translarna for nmDMD, Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment